BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focused on developing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today that its management will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference, to be held from September 14-16, 2026 in New York City.
The company's Chief Financial Officer, Hernan Levett, will deliver the presentation on September 16, 2026 from 12:30 PM to 1:00 PM ET at the Kennedy II room on the 4th floor of the Lotte New York Palace. Additionally, BioVersys' Chief Executive Officer, Dr. Marc Gitzinger, will provide an on-demand presentation available starting September 11, 2026 at 7:00 AM ET, with replay accessible for 90 days via the H.C. Wainwright platform or through the investor section of the BioVersys website. Both executives will be available for one-on-one meetings with registered attendees during the conference.
This participation comes at a pivotal time for BioVersys, which is advancing a pipeline addressing critical antimicrobial resistance threats. The most advanced program, BV100, targets nosocomial infections caused by Acinetobacter baumannii and is currently in Phase 3 development. Another key program, alpibectir, for tuberculosis, is in Phase 2 and is being developed in collaboration with GlaxoSmithKline (GSK) and a consortium led by the University of Lille, France. These efforts are grounded in the company's proprietary technology platforms, TRIC and Ansamycin Chemistry, which are designed to overcome resistance mechanisms, block virulence production, and influence bacterial pathogenesis to create new treatment options for antimicrobial and microbiome-related diseases.
The announcement underscores the growing urgency of addressing antimicrobial resistance (AMR), which the World Health Organization has identified as one of the top global public health threats. BioVersys' focus on resistant hospital-acquired infections and tuberculosis highlights its role in tackling infections for which conventional antibiotics are becoming increasingly ineffective. By presenting at a major investment conference, the company aims to attract attention from investors interested in supporting novel approaches to combat AMR, an area of high unmet medical need. The presentation will provide an opportunity for potential investors to gain insight into BioVersys' clinical programs, strategic partnerships, and future plans.
With its base in the biotech hub of Basel, Switzerland, BioVersys is well-positioned to leverage its research and development capabilities. The company's participation in the H.C. Wainwright conference is expected to raise its profile among institutional investors and potentially facilitate new collaborations or funding opportunities, which are crucial for advancing late-stage clinical trials and eventually bringing new antibacterial treatments to market.
